Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $17.00 Average PT from Analysts

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have earned a consensus recommendation of “Buy” from the nine research firms that are covering the firm, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $17.00.

VYGR has been the topic of a number of recent research reports. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Wedbush began coverage on shares of Voyager Therapeutics in a report on Friday, November 29th. They issued an “outperform” rating and a $11.00 target price for the company. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Finally, Leerink Partners initiated coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock.

Insider Buying and Selling

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.53% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Great Point Partners LLC purchased a new position in Voyager Therapeutics in the 2nd quarter valued at approximately $12,668,000. Armistice Capital LLC boosted its position in Voyager Therapeutics by 11.3% during the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after purchasing an additional 528,000 shares in the last quarter. FMR LLC grew its holdings in Voyager Therapeutics by 26.9% in the third quarter. FMR LLC now owns 92,498 shares of the company’s stock valued at $541,000 after purchasing an additional 19,622 shares during the last quarter. Verition Fund Management LLC purchased a new position in shares of Voyager Therapeutics in the third quarter valued at $216,000. Finally, Erste Asset Management GmbH acquired a new position in shares of Voyager Therapeutics during the 3rd quarter worth $6,192,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Price Performance

NASDAQ VYGR opened at $5.73 on Tuesday. The company has a fifty day moving average of $6.46 and a two-hundred day moving average of $7.05. The company has a market capitalization of $313.01 million, a PE ratio of 8.07 and a beta of 0.90. Voyager Therapeutics has a 1 year low of $5.19 and a 1 year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the prior year, the firm earned ($0.59) EPS. On average, research analysts expect that Voyager Therapeutics will post -0.89 earnings per share for the current year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.